医药导报2026，Vol.45Issue(6)：1001-1008,8.DOI:10.3870/j.issn.1004-0781.2026.06.008
蛋白降解靶向嵌合体靶向治疗炎症免疫性疾病研究进展
Advances in Proteolysis-Targeting Chimera-Targeted Therapeutics for Inflammatory and Autoimmune Diseases
摘要
Abstract
Inflammatory and immune diseases are characterized by complex pathogenesis and protracted disease courses.Current treatment approaches are often limited by suboptimal efficacy,insufficient targeting specificity,and poor tolerability.Pro-teolysis-targeting chimeras(PROTACs)specifically degrade target proteins via mediating the ubiquitin-proteasome system,offer-ing a novel strategy to overcome the limitations of traditional therapies.This review systematically delineates the research advances of PROTAC technology in inflammatory and immune diseases,with particular emphasis on elucidating its targeted intervention mechanisms against pivotal signaling cascades and regulatory nodes.These encompass the JAK-STAT axis,BTK,IRAK,RIPK,as well as epigenetic modulators and oxidative stress sensors,notably HDACs and Keap1.Furthermore,this paper discusses the challenges encountered in the clinical translation process,optimization strategies,and future directions for development.关键词
蛋白降解靶向嵌合体/靶向治疗/炎症免疫性疾病Key words
Proteolysis-targeting chimera/Targeted therapeutics/Inflammatory and immune disease分类
医药卫生引用本文复制引用
徐茹,朱蕾..蛋白降解靶向嵌合体靶向治疗炎症免疫性疾病研究进展[J].医药导报,2026,45(6):1001-1008,8.基金项目
中国医学科学院医学与健康科技创新工程(2021-I2M-1-005,2025-I2M-KJ-009) （2021-I2M-1-005,2025-I2M-KJ-009）
北京协和医院中央高水平医院临床科研专项(2022-PUMCH-C-025). （2022-PUMCH-C-025）
